Skip to main content
Premium Trial:

Request an Annual Quote

Warnex to Restate Financial Statements

NEW YORK (GenomeWeb News) – Warnex said today that it would restate its financial statements for prior years due to a non-cash accounting error in its presentation of the debt component of its 2002 and 2004 convertible debentures.
 
The Laval, Quebec-based bioanalytical services and lab testing firm said that due to the accounting error the liability component of the debentures was understated by CDN$615,255 (US$627,691) as of Dec. 31, 2006, and its net loss was understated by $313,597, or $.01 per share, for 2006. The firm said it would restate the 2006 comparative numbers when it reports its year-end 2007 results.
 
For fiscal year 2006, Warnex reported revenues of $21.1 million and a net loss of $17.9 million, or $.34 per share.
 
Warnex also said that although it would not file amended interim financial statements for the year 2007, it would restate the comparative 2007 numbers when disclosing its 2008 interim financial results.
 
“Although regrettable, this specific and isolated situation, which does not impact the cash flow of the company, is being rapidly corrected and does not impact the future outlook of the company,” Mark Busgang, president and CEO of Warnex, said in a statement.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.